Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
Health Canada announced May 1 approval of a second generic semaglutide injection, filed by Canadian-based Apotex as a generic version of Novo Nordisk's Ozempic. The April 28, 2026 first approval (Dr. Reddy's Laboratories) was followed three days later by the Apotex green light, making Canada the first G7 country with two approved generic semaglutide products. Health Canada is currently reviewing seven additional generic submissions. Patent context: Canadian patent protection lapsed earlier than expected after a Novo Nordisk maintenance-fee issue. Sandoz separately targets a Q3 2026 commercial launch and the company has projected 45-90% price reductions versus brand-name Ozempic. US patent protection runs through December 2031.
Foley & Lardner published a May 2026 client memo translating the FDA's April 22 Category 2 removal of 12 peptides for the compounding-pharmacy audience. Key framing: the removal does not, by itself, place these substances on the 503A bulks list, and the peptides will exist in a regulatory gray zone until the PCAC meets July 23–24 to consider seven of them (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) and the FDA takes final action — which under standard rulemaking timelines could run more than a year past the meeting. The piece joins the Orrick May 2026 503B GLP-1 memo, the FDA Law Blog Pep(tide) Rally analysis (April 23), Holt Law's California Sherman-Law alert, and the Frier Levitt April peptide update as the legal cluster compounders are reading ahead of the meeting.
Camurus's Oclaiz (CAM2029) — a once-monthly subcutaneous octreotide FluidCrystal depot delivered via prefilled autoinjector — has an FDA Prescription Drug User Fee Act target action date of June 10, 2026, following an October 2024 Complete Response Letter tied to a third-party manufacturer's cGMP inspection. CAM2029's ACROINNOVA Phase 3 program documented approximately five-fold higher bioavailability versus the currently approved long-acting intramuscular octreotide formulation. The June PDUFA sets up a back-to-back acromegaly decision pair with Crinetics' Palsonify (paltusotine), already approved in the EU on April 27 and reported $10.3M in Q1 US net product revenue (covered above). Both target the same patient population through different routes — once-daily oral nonpeptide vs once-monthly subcutaneous peptide depot.
NPR ran a consumer-facing explainer May 6 of the Medicare GLP-1 Bridge demonstration that begins July 1, 2026 and runs through December 31, 2027. Eligible Medicare Part D beneficiaries can access Wegovy, Foundayo, and the Zepbound KwikPen formulation for a $50/month copay through the Bridge after meeting prior-authorization criteria. The piece consolidates a regulatory thread that has been jagged in mainstream coverage — the BALANCE pilot's collapse in late April when CVS pulled out, the Trump-administration extension of the Bridge to 2027, and the May 2026 confirmation that state Medicaid agencies can opt in. NPR's translation arrives in the same window as Novo's May 6 Q1 print and the Hims & Hers May 11 print, both of which are partly leveraged on Bridge eligibility expanding the addressable patient base.
Lantheus's PNT2003 (lutetium Lu 177 dotatate ANDA-route radioequivalent) is positioned to enter its final FDA approval window after the 30-month regulatory stay expires in June 2026. The product would be the second SSTR2 PRRT in the US neuroendocrine tumor market alongside Novartis's Lutathera, which has held the category since 2018. The regulatory framework: PNT2003 received tentative approval March 2; PYLARIFY TruVu (piflufolastat F 18) high-throughput PSMA PET formulation approved March 6. ITM's Lu-edotreotide-177 (ITM-11) follows on a separate August 28, 2026 PDUFA, and Crinetics' CRN09682 SSTR2 non-peptide drug conjugate is in Phase 1/2 BRAVESST2 — making 2026 a defining year for the SSTR2 PRRT competitive frame.
ITM Isotope Technologies Munich's Lu-edotreotide-177 (branded ITM-11), a peptide radioligand therapy targeting somatostatin receptor 2 (SSTR2) in gastroenteropancreatic neuroendocrine tumors, has an FDA decision goal of August 28, 2026. If approved, ITM-11 would expand US PRRT options beyond Novartis's Lutathera, which has held the SSTR2 PRRT category since 2018. Companion radiopharmaceutical kit Ga 68 edotreotide (LNTH-2501) supports PET imaging for SSTR-positive NETs. The August PDUFA sits alongside the July 23–24 PCAC meeting on seven 503A peptides and Roche's mid-2026 enicepatide+petrelintide combination Phase 2 start as the next-quarter peptide regulatory inflection points.
Holt Law's April update on BPC-157 reminded compounders and clinics that the FDA's Category 2 removal does not authorize compounding on its own — the seven-peptide PCAC meeting on July 23–24 is required first, followed by formal rulemaking. The alert flagged California-specific exposure: the state's Sherman Food, Drug and Cosmetic Law prohibits the sale or distribution of new drugs that have not received FDA or state approval, and prescribing or dispensing BPC-157 outside approved pathways could expose physicians to significant legal risks separate from federal enforcement. The piece complements the firm's January 2 critical-status alert and the broader 2026 state-by-state compounding-enforcement divergence between California (30+ Board of Pharmacy actions since 2023) and Texas (more permissive for licensed 503A operations).
An FDA Adverse Event Reporting System (FAERS) entry logged April 30 surfaced publicly May 4, documenting hepatic failure in a 56-year-old male patient on Foundayo (orforglipron). The case was marked for expedited review and could have occurred at or before April 15 — Foundayo only launched April 9. There have been 34 total Foundayo FAERS reports so far, with two considered serious. LLY traded down nearly 3% premarket — hitting roughly $936 — before recovering on Lilly's response. Foundayo's label carries a warning that the medication is 'not recommended for use in patients with severe hepatic impairment' (orforglipron is primarily hepatically metabolized), but mild and moderate liver impairment is allowed at standard dose.
FormBlends and the FDA Law Blog 'Pep(tide) Rally' analyses surfaced a state-level compliance map that compounders are now navigating ahead of the July PCAC. California's Board of Pharmacy has issued 30+ enforcement actions against peptide-compounding pharmacies since 2023, scrutinizing both quality and technical regulatory compliance. Texas Board of Pharmacy enforcement has historically focused on egregious quality violations rather than minor technical issues, making the state more accessible for licensed 503A and 503B operations under physician prescription. The gap matters because telehealth platforms route fulfillment through state-by-state pharmacy networks; a CVS or compounder routing decision in 2026 is now a state-policy decision as much as a federal one.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
The FDA's PCAC public docket FDA-2025-N-6895 is now accepting written comments on the proposed addition of seven peptides to the Section 503A bulk drug substances list ahead of the July 23–24 advisory committee meeting at White Oak. Day 1 will cover BPC-157, KPV, TB-500, and MOTs-C; Day 2 will cover Emideltide (DSIP), Semax, and Epitalon. Comments received by July 9 are guaranteed to be presented to the committee, and the docket closes July 22. The window gives compounders, prescribers, and patient advocates roughly twelve weeks to formally submit clinical evidence, pharmacovigilance data, and access arguments.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
Crinetics Pharmaceuticals announced April 27 that the European Commission approved Palsonify (paltusotine), a selectively-targeted somatostatin receptor type 2 nonpeptide agonist, as the first once-daily oral therapy for acromegaly in adults across all 27 EU member states plus three EEA countries. The approval rests on two pivotal Phase 3 trials in medical-naïve and previously treated patients, with diarrhea, abdominal pain, and nausea reported as the most common adverse reactions and no serious adverse events in the randomized portion. First launches are planned for Germany and Austria, marking Crinetics' first regulatory approval outside the U.S. and a competitive challenge to injectable somatostatin analogs.
STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.
The FDA announced April 28 that it has completed first tests of a real-time data system that allows agency scientists to view safety and effectiveness data from clinical trial patients as it is collected — shifting from the traditional stop-and-go batch reporting model to a continuous live data stream. The pilot affects all therapeutic categories including peptide drugs, with implications for trial timelines, regulatory review speed, and adverse-event detection. Industry observers see the move as part of broader systemic agency change under the new HHS leadership.
FormBlends, a telehealth platform focused on medically supervised GLP-1 and peptide therapy, released its 2026 State of Peptides and GLP-1 Regulation Report on April 28. The report maps how RFK Jr.'s HHS, the FDA Center for Drug Evaluation and Research, and the next-generation obesity pipeline from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access for weight management, metabolic health, and peptide therapy through the end of the decade. The report follows the April 22 formal removal of 12 peptides from FDA Category 2 and previews the July 23-24 PCAC meeting.
Pharmacy law firm Holt Law published a detailed regulatory analysis of how the FDA's April 22 Category 2 removals interact with state pharmacy boards, 503A vs 503B compounding pathways, and physician prescribing requirements. The analysis emphasizes that Category 2 removal is not the same as 503A bulk-list inclusion, and that compounding pharmacies face material legal risk if they begin producing reclassified peptides before the July 23-24 PCAC meeting. The piece is a working reference for pharmacy operations preparing for the post-PCAC environment.
JustCare Health published a substantial analysis of the FDA's evolving peptide stance, framing the Category 2 removal as a practical inflection point that begins to resolve the gray-market dynamic that built up after the 2023 restrictions. The piece documents the Alliance for Pharmacy Compounding's position and emphasizes the gap between compounding-pharmacy operational readiness and patient demand. The piece is among the most-read peptide policy articles in the consumer-health press this week.